These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 23246637)

  • 21. Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis.
    Cheung AC; Lammers WJ; Murillo Perez CF; van Buuren HR; Gulamhusein A; Trivedi PJ; Lazaridis KN; Ponsioen CY; Floreani A; Hirschfield GM; Corpechot C; Mayo MJ; Invernizzi P; Battezzati PM; Parés A; Nevens F; Thorburn D; Mason AL; Carbone M; Kowdley KV; Bruns T; Dalekos GN; Gatselis NK; Verhelst X; Lindor KD; Lleo A; Poupon R; Janssen HLA; Hansen BE;
    Clin Gastroenterol Hepatol; 2019 Sep; 17(10):2076-2084.e2. PubMed ID: 30616022
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of S-adenosyl-L-methionine on liver biochemistry and quality of life in patients with primary biliary cholangitis treated with ursodeoxycholic acid. A prospective, open label pilot study.
    Wunsch E; Raszeja-Wyszomirska J; Barbier O; Milkiewicz M; Krawczyk M; Milkiewicz P
    J Gastrointestin Liver Dis; 2018 Sep; 27(3):273-279. PubMed ID: 30240471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10 mg/kg or 20 mg/kg. Dutch Multicentre PBC Study Group.
    Van Hoogstraten HJ; De Smet MB; Renooij W; Breed JG; Engels LG; Den Ouden-Muller JW; Rijk MC; Smit AM; Zwertbroek R; Hop WC; van Berge Henegouwen GP; Schalm SW; van Buuren HR
    Aliment Pharmacol Ther; 1998 Oct; 12(10):965-71. PubMed ID: 9798800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early biochemical response to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis.
    Azemoto N; Abe M; Murata Y; Hiasa Y; Hamada M; Matsuura B; Onji M
    J Gastroenterol; 2009; 44(6):630-4. PubMed ID: 19370305
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum vitamin D level is associated with disease severity and response to ursodeoxycholic acid in primary biliary cirrhosis.
    Guo GY; Shi YQ; Wang L; Ren X; Han ZY; Guo CC; Cui LN; Wang JB; Zhu J; Wang N; Zhang J; Cai Y; Han Y; Zhou XM; Fan DM
    Aliment Pharmacol Ther; 2015 Jul; 42(2):221-30. PubMed ID: 25982180
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in patients with primary biliary cirrhosis. Dutch Multi-Centre PBC Study Group.
    van Hoogstraten HJ; Hansen BE; van Buuren HR; ten Kate FJ; van Berge-Henegouwen GP; Schalm SW
    J Hepatol; 1999 Aug; 31(2):256-62. PubMed ID: 10453938
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid.
    Angulo P; Lindor KD; Therneau TM; Jorgensen RA; Malinchoc M; Kamath PS; Dickson ER
    Liver; 1999 Apr; 19(2):115-21. PubMed ID: 10220741
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group.
    Poupon RE; Huet PM; Poupon R; Bonnand AM; Nhieu JT; Zafrani ES
    Hepatology; 1996 Nov; 24(5):1098-103. PubMed ID: 8903382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ursodeoxycholic Acid Therapy in Patients with Primary Biliary Cholangitis with Limited Liver Transplantation Availability.
    Melchor-Mendoza YK; Martínez-Benítez B; Mina-Hawat A; Rodríguez-Leal G; Duque X; Moran-Villota S
    Ann Hepatol; 2017; 16(3):430-435. PubMed ID: 28425413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Retrospective analysis of autoimmune hepatitis-primary biliary cirrhosis overlap syndrome in Korea: characteristics, treatments, and outcomes.
    Park Y; Cho Y; Cho EJ; Kim YJ
    Clin Mol Hepatol; 2015 Jun; 21(2):150-7. PubMed ID: 26157752
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis.
    Angulo P; Batts KP; Therneau TM; Jorgensen RA; Dickson ER; Lindor KD
    Hepatology; 1999 Mar; 29(3):644-7. PubMed ID: 10051462
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.
    Corpechot C; Abenavoli L; Rabahi N; Chrétien Y; Andréani T; Johanet C; Chazouillères O; Poupon R
    Hepatology; 2008 Sep; 48(3):871-7. PubMed ID: 18752324
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy.
    Lammers WJ; Hirschfield GM; Corpechot C; Nevens F; Lindor KD; Janssen HL; Floreani A; Ponsioen CY; Mayo MJ; Invernizzi P; Battezzati PM; Parés A; Burroughs AK; Mason AL; Kowdley KV; Kumagi T; Harms MH; Trivedi PJ; Poupon R; Cheung A; Lleo A; Caballeria L; Hansen BE; van Buuren HR;
    Gastroenterology; 2015 Dec; 149(7):1804-1812.e4. PubMed ID: 26261009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a retrospective study of 115 cases of autoimmune liver disease.
    Heurgué A; Vitry F; Diebold MD; Yaziji N; Bernard-Chabert B; Pennaforte JL; Picot R; Louvet H; Frémond L; Geoffroy P; Schmit JL; Cadiot G; Thiéfin G
    Gastroenterol Clin Biol; 2007 Jan; 31(1):17-25. PubMed ID: 17273128
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis.
    Barron-Millar B; Ogle L; Mells G; Flack S; Badrock J; Sandford R; Kirby J; Palmer J; Jopson L; Brain J; Smith GR; Rushton S; Hegade VS; Jones R; Rushbrook S; Thorburn D; Ryder S; Hirschfield G; ; Dyson JK; Jones DEJ
    Hepatology; 2021 Dec; 74(6):3269-3283. PubMed ID: 34129689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response.
    Trivedi PJ; Bruns T; Cheung A; Li KK; Kittler C; Kumagi T; Shah H; Corbett C; Al-Harthy N; Acarsu U; Coltescu C; Tripathi D; Stallmach A; Neuberger J; Janssen HL; Hirschfield GM
    J Hepatol; 2014 Jun; 60(6):1249-58. PubMed ID: 24548531
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of colchicine in patients with primary biliary cirrhosis poorly responsive to ursodiol and methotrexate.
    Lee YM; Kaplan MM
    Am J Gastroenterol; 2003 Jan; 98(1):205-8. PubMed ID: 12526960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ursodeoxycholic acid enhances fractional calcium absorption in primary biliary cirrhosis.
    Verma A; Maxwell JD; Ang L; Davis T; Hodges S; Northfield TC; Zaidi M; Pazianas M
    Osteoporos Int; 2002 Aug; 13(8):677-82. PubMed ID: 12181628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RANK/RANKL Acts as a Protective Factor by Targeting Cholangiocytes in Primary Biliary Cholangitis.
    Hao YL; Bian ZL; Ju LL; Liu Y; Qin G
    Dig Dis Sci; 2020 Feb; 65(2):470-479. PubMed ID: 31377883
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation.
    Kim WR; Poterucha JJ; Jorgensen RA; Batts KP; Homburger HA; Dickson ER; Krom RA; Wiesner RH; Lindor KD
    Hepatology; 1997 Jul; 26(1):22-6. PubMed ID: 9214447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.